Article
Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study.
Pathology - 1 Jun 2024
Tedjaseputra Aditya, Roy Sukanya, Htun Kay, Oh Danielle, McQuilten Zoe, Yeh Paul, Bennett Ashwini, Low Michael Sze Yuan, Chunilal Sanjeev, Wood Erica M, Shortt Jake
Abstract excerpt
Early induction response assessment with day-21 bone marrow (D21-BM) is commonly performed in patients with FLT3-mutated acute myeloid leukaemia (AML), where detection of residual leukaemia (RL; blasts ≥5%) typically results in the administration of a second induction course. However, whether D21-BM results predict for RL at the end of first induction has not been systematically assessed. This study evaluates the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.